Concomitant DMARD Therapies Increase Adalimumab Serum Concentrations in Patients with Rheumatic Diseases

Patients with rheumatoid arthritis (RA) who are treated with adalimumab plus methotrexate (MTX) have higher serum trough levels of adalimumab and a better clinical response to therapy than patients treated with adalimumab alone [Pouw MF et al. Ann Rheum Dis 2013]. This article discusses the effect on adalimumab serum concentrations in patients with RA or psoriatic arthritis taking concomitant MTX and concomitant disease-modifying antirheumatic drugs (DMARDs) other than MTX.